| 000 | 01815 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250517083643.0 | ||
| 264 | 0 | _c20170123 | |
| 008 | 201701s 0 0 eng d | ||
| 022 | _a1543-8392 | ||
| 024 | 7 |
_a10.1021/acs.molpharmaceut.5b00670 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMassey, Ashley S | |
| 245 | 0 | 0 |
_aPotentiating the Anticancer Properties of Bisphosphonates by Nanocomplexation with the Cationic Amphipathic Peptide, RALA. _h[electronic resource] |
| 260 |
_bMolecular pharmaceutics _cApr 2016 |
||
| 300 |
_a1217-28 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAlendronate _xchemistry |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xchemistry |
| 650 | 0 | 4 |
_aBone Density Conservation Agents _xchemistry |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 |
_aCell Survival _xdrug effects |
| 650 | 0 | 4 |
_aDiphosphonates _xchemistry |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImidazoles _xchemistry |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 |
_aNanoparticles _xchemistry |
| 650 | 0 | 4 |
_aPeptides _xchemistry |
| 650 | 0 | 4 |
_aProstatic Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aXenograft Model Antitumor Assays |
| 650 | 0 | 4 | _aZoledronic Acid |
| 700 | 1 | _aPentlavalli, Sreekanth | |
| 700 | 1 | _aCunningham, Richard | |
| 700 | 1 | _aMcCrudden, Cian M | |
| 700 | 1 | _aMcErlean, Emma M | |
| 700 | 1 | _aRedpath, Philip | |
| 700 | 1 | _aAli, Ahlam A | |
| 700 | 1 | _aAnnett, Stephanie | |
| 700 | 1 | _aMcBride, John W | |
| 700 | 1 | _aMcCaffrey, Joanne | |
| 700 | 1 | _aRobson, Tracy | |
| 700 | 1 | _aMigaud, Marie E | |
| 700 | 1 | _aMcCarthy, Helen O | |
| 773 | 0 |
_tMolecular pharmaceutics _gvol. 13 _gno. 4 _gp. 1217-28 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1021/acs.molpharmaceut.5b00670 _zAvailable from publisher's website |
| 999 |
_c25806582 _d25806582 |
||